Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00844883 · ClinicalTrials.gov registry record · Phase 2
Study of Sorafenib and Transarterial Chemoembolization (TACE) to Treat Hepatocellular Carcinoma
A Phase 2 study, sponsored by Yale University.
- Completed
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
NCT00844883 is a Phase 2 study that has completed, run by Yale University. The registered enrollment target is 50 participants.
The verdict
NCT00844883, a Phase 2 study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
Study Summary
This study will combine two therapies to treat patients with unresectable hepatocellular carcinoma; sorafenib, and drug eluting beads delivered intra-arterially. The purpose of the study is to establish the safety and the effectiveness of the combination therapy. The investigators hypothesize that the combination of the two therapies will not result in greater toxicities to patients than that expected for either therapy given alone.
Interventions
- DRUG sorafenib
- PROCEDURE LC Bead-TACE
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2009-02 |
| Est. Completion | 2015-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00844883
The ClinicalTrials.gov registry entry for NCT00844883 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which sorafenib is the first listed.
NCT00844883 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00844883 about?
NCT00844883 is a clinical study titled "Study of Sorafenib and Transarterial Chemoembolization (TACE) to Treat Hepatocellular Carcinoma". This study will combine two therapies to treat patients with unresectable hepatocellular carcinoma; sorafenib, and drug eluting beads delivered intra-arterially. The purpose of the study is to establish the safety and the effectiveness of the combination therapy. The investigators hypothesize that t...
What is the current status of trial NCT00844883?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2009-02. Estimated completion is 2015-03.
What interventions are being tested in trial NCT00844883?
The interventions under investigation include: sorafenib (DRUG), LC Bead-TACE (PROCEDURE).
Who is sponsoring clinical trial NCT00844883?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.